PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22466910-5	2012	Changes in serum creatinine and estimated GFR to month 12 were significantly in favor of CNI-free patients.	Creatinine	17-27	calcineurin binding protein 1	Homo sapiens	89-92	
18217899-7	2008	RESULTS: Calcineurin inhibitor minimization using mycophenolate mofetil or sirolimus may be associated with a modest increase in creatinine clearance (CrCl) and a decrease in serum creatinine (SCr) in the short term.	Creatinine	129-139	calcineurin binding protein 1	Homo sapiens	9-30	
18217899-7	2008	RESULTS: Calcineurin inhibitor minimization using mycophenolate mofetil or sirolimus may be associated with a modest increase in creatinine clearance (CrCl) and a decrease in serum creatinine (SCr) in the short term.	Creatinine	181-191	calcineurin binding protein 1	Homo sapiens	9-30	
17919619-1	2007	BACKGROUND: Proliferation signal inhibitors (PSI) facilitate reduction in calcineurin inhibitor exposure resulting in an improvement in creatinine clearance (CrCl) in cardiac transplant recipients with renal dysfunction.	Creatinine	136-146	calcineurin binding protein 1	Homo sapiens	74-95	
12372044-12	2002	In the five patients with improved renal function, serum creatinine levels decreased significantly (2.4 +/- 0.3 mg/dL to 1.5 +/- 0.1 mg/dL, p < 0.05) by a mean of 7.2 months (range 5-10 months) after conversion from CNI to rapamycin-based immunosuppression.	Creatinine	57-67	calcineurin binding protein 1	Homo sapiens	219-222	
17133564-2	2006	In this prospective, multicenter, randomized study, chronic CNI-related renal dysfunction was defined by an increase in serum creatinine with values >140 micromol/L and <300 micromol/L.	Creatinine	126-136	calcineurin binding protein 1	Homo sapiens	60-63	
15943635-4	2005	CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p < 0.00001) at 1 year compared to continued CNI and sirolimus therapy.	Creatinine	162-172	calcineurin binding protein 1	Homo sapiens	0-3	
15237243-9	2004	A Cox proportional hazards model adjusting for baseline covariates including age, gender, race, type of transplant, delayed graft function, baseline blood pressure and random serum glucose and cholesterol demonstrated that only calcineurin inhibitor dose reduction but not withdrawal, older age, delayed graft function, higher serum creatinine at the time of intervention, and higher diastolic blood pressure and serum glucose, correlated with graft loss.	Creatinine	333-343	calcineurin binding protein 1	Homo sapiens	228-249